Clinical Trials Directory

Trials / Terminated

TerminatedNCT02821819

Random-start Ovarian Stimulation in Egg-donors (ROSE)

Random-start Ovarian Stimulation in Egg-donors (ROSE) Trial: a Self-controlled Study

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Instituto Bernabeu · Academic / Other
Sex
Female
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

The purpose of this prospective single-center study is to evaluate the laboratory outcome after random start ovarian stimulation in oocyte donors. The study will be performed in egg-donors but this type of treatment has the potential to be implemented in general infertility population.

Detailed description

The study group will start ovarian stimulation randomly in different moments throughout the menstrual cycle. Randomization will take place on day 2-3 of the menstrual cycle, according to a list of random allocation of treatments and egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase starting at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. Egg-donors will receive urinary follicle stimulating hormone (FSH) 150-225 IU/d in gonadotropin-releasing hormone (GnRH) antagonist protocol with cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation and a GnRH agonist trigger with triptorelin 0,2 mg to induce the final follicular maturation. Transvaginal ultrasound and serum analysis (estradiol, progesterone, LH and FSH) will be included for cycle monitoring.

Conditions

Interventions

TypeNameDescription
OTHERRandom start ovarian stimulationEgg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
DRUGGonadotrophinsUrinary FSH 150-225 IU/d
DRUGGnRH antagonistCetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
DRUGGnRH agonistGnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.

Timeline

Start date
2017-01-10
Primary completion
2018-01-12
Completion
2018-01-12
First posted
2016-07-04
Last updated
2019-08-19
Results posted
2019-08-19

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02821819. Inclusion in this directory is not an endorsement.